{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:56:39Z","timestamp":1790088999270,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002562","name":"Sunchon National University","doi-asserted-by":"publisher","award":["2025-G018"],"award-info":[{"award-number":["2025-G018"]}],"id":[{"id":"10.13039\/501100002562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05191-2","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:41:59Z","timestamp":1774334519000},"page":"13257-13274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Physiologically based pharmacokinetic modeling of immediate-release and extended-release formulations of doxazosin, an alpha-1 adrenergic receptor antagonist, with model simulations for patients with liver disease"],"prefix":"10.1007","volume":"399","author":[{"given":"Seung-Hyun","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"5191_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/clpt.1986.224","volume":"40","author":"RV Carlson","year":"1986","unstructured":"Carlson RV, Bailey RR, Begg EJ, Cowlishaw MG, Sharman JR (1986) Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 40:561\u2013566","journal-title":"Clin Pharmacol Ther"},{"key":"5191_CR2","first-page":"61","volume":"30","author":"H-Y Cho","year":"2000","unstructured":"Cho H-Y, Kim S-J, Shim Y-S, Lim D-K, Oh I-J, Moon J-D, Lee Y-B (2000) Bioequivalence of Cardil tablet to Cardura tablet (doxazosin 2 mg). J Pharm Investig 30:61\u201365","journal-title":"J Pharm Investig"},{"key":"5191_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1046\/j.1365-2125.1999.00067.x","volume":"48","author":"M Chung","year":"1999","unstructured":"Chung M, Vashi V, Puente J, Sweeney M, Meredith P (1999) Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 48:678\u2013687","journal-title":"Br J Clin Pharmacol"},{"key":"5191_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2165\/00003088-198916060-00004","volume":"16","author":"EL Conway","year":"1989","unstructured":"Conway EL, McNeil JJ, Meng L, Drummer OH, Howes LG, Raymond K, Louis WJ (1989) Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects. Clin Pharmacokinet 16:387\u2013391","journal-title":"Clin Pharmacokinet"},{"key":"5191_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00003495-199957010-00002","volume":"57","author":"KL Cooper","year":"1999","unstructured":"Cooper KL, McKiernan JM, Kaplan SA (1999) \u03b1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 57:9\u201317","journal-title":"Drugs"},{"key":"5191_CR6","unstructured":"DrugBank Doxazosin.\u00a0https:\/\/go.drugbank.com\/drugs\/DB00590.\u00a0Accessed 9 Apr 2025"},{"key":"5191_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","volume":"47","author":"AN Edginton","year":"2008","unstructured":"Edginton AN, Willmann S (2008) Physiology-based simulations of a pathological condition. Clin Pharmacokinet 47:743\u2013752","journal-title":"Clin Pharmacokinet"},{"key":"5191_CR8","doi-asserted-by":"publisher","first-page":"G78","DOI":"10.1016\/0002-9149(87)90162-7","volume":"59","author":"HL Elliott","year":"1987","unstructured":"Elliott HL, Meredith PA, Reid JL (1987) Pharmacokinetic overview of doxazosin. Am J Cardiol 59:G78\u2013G81","journal-title":"Am J Cardiol"},{"key":"5191_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/00003495-199549020-00011","volume":"49","author":"B Fulton","year":"1995","unstructured":"Fulton B, Wagstaff AJ, Sorkin EM (1995) Doxazosin. Drugs 49:295\u2013320","journal-title":"Drugs"},{"key":"5191_CR10","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2165\/00003495-200565140-00008","volume":"65","author":"DR Goldsmith","year":"2005","unstructured":"Goldsmith DR, Plosker GL (2005) Doxazosin gastrointestinal therapeutic system. Drugs 65:2037\u20132047","journal-title":"Drugs"},{"key":"5191_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40495-021-00266-5","volume":"7","author":"AN Han","year":"2021","unstructured":"Han AN, Han BR, Zhang T, Heimbach T (2021) Hepatic impairment physiologically based pharmacokinetic model development: current challenges. Curr Pharmacol Rep 7:213\u2013226","journal-title":"Curr Pharmacol Rep"},{"key":"5191_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40005-013-0077-0","volume":"43","author":"HA Hazzah","year":"2013","unstructured":"Hazzah HA, El-Massik MA, Abdallah OY, Abdelkader H (2013) Preparation and characterization of controlled-release doxazosin mesylate pellets using a simple drug layering-aquacoating technique. J Pharm Investig 43:333\u2013342","journal-title":"J Pharm Investig"},{"key":"5191_CR13","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02995-4","volume":"26","author":"J-H Jang","year":"2024","unstructured":"Jang J-H, Jeong S-H (2024) Pharmacokinetic prediction of immediate- and extended-release tablets for patients with liver disease using whole body physiologically-based pharmacokinetic modeling for the antipsychotic drug quetiapine. AAPS PharmSciTech 26:8","journal-title":"AAPS PharmSciTech"},{"key":"5191_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-025-00938-3","author":"J-H Jang","year":"2025","unstructured":"Jang J-H, Jeong S-H (2025) Development of a physiologically-based pharmacokinetic model for quantitative interpretation of transdermal drug delivery of rotigotine, a dopamine agonist for treating Parkinson\u2019s disease. Eur J Drug Metab Pharmacokinet. https:\/\/doi.org\/10.1007\/s13318-025-00938-3","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"5191_CR15","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1016\/j.xphs.2022.08.035","volume":"111","author":"S-H Jeong","year":"2022","unstructured":"Jeong S-H, Jang J-H, Lee Y-B (2022) Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: exploration of doses for CYP2C9 genotypes and patients with cirrhosis. J Pharm Sci 111:3174\u20133184","journal-title":"J Pharm Sci"},{"key":"5191_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A (2010) A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49:189\u2013206","journal-title":"Clin Pharmacokinet"},{"key":"5191_CR17","first-page":"20","volume":"29","author":"S Kaewvichit","year":"2007","unstructured":"Kaewvichit S, Thongsawat S, Taesotikul W, Wongsinsup C, Yotsawimonwat S, Duangrat C, Niwatananun K, Niwatananun W (2007) Bioequivalence study of doxazosin tablets in healthy thai male volunteers. Thai J Pharmacol 29:20","journal-title":"Thai J Pharmacol"},{"key":"5191_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/bmc.666","volume":"20","author":"YJ Kim","year":"2006","unstructured":"Kim YJ, Lee Y, Kang MJ, Huh JS, Yoon M, Lee J, Choi YW (2006) High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. Biomed Chromatogr 20:1172\u20131177","journal-title":"Biomed Chromatogr"},{"key":"5191_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FJC.0000000000001597","volume":"84","author":"S Kulkarni","year":"2024","unstructured":"Kulkarni S, Jenkins D, Dhar A, Mir F (2024) Treating lows: management of orthostatic hypotension. J Cardiovasc Pharmacol 84:303\u2013315","journal-title":"J Cardiovasc Pharmacol"},{"key":"5191_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/03639040601012999","volume":"33","author":"YH Kwon","year":"2007","unstructured":"Kwon YH, Sun GH, Jung YS, Chun IK (2007) Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in korean healthy volunteers. Drug Dev Ind Pharm 33:824\u2013829","journal-title":"Drug Dev Ind Pharm"},{"key":"5191_CR21","first-page":"40","volume":"62","author":"R Mathur","year":"2014","unstructured":"Mathur R, Nayak S, Sivaramakrishnan R, Jain V (2014) Role of alpha blockers in hypertension with benign prostatic hyperplasia. J Assoc Physicians India 62:40\u201344","journal-title":"J Assoc Physicians India"},{"key":"5191_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/00498258809055143","volume":"18","author":"PA Meredith","year":"1988","unstructured":"Meredith PA, L. EH, W. KA, J. V, Reid JL (1988) Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica 18:123\u2013129","journal-title":"Xenobiotica"},{"key":"5191_CR23","doi-asserted-by":"publisher","unstructured":"Peeriga R, Manubolu K (2024)\u00a0Effect of renal and hepatic diseases on pharmacokinetics. In: Manubolu K, Peeriga R, Chandrasekhar KB (eds) A short guide to clinical pharmacokinetics. Singapore: Springer Nature Singapore, pp 67\u201395. https:\/\/doi.org\/10.1007\/978-981-97-4283-7_5","DOI":"10.1007\/978-981-97-4283-7_5"},{"key":"5191_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/009127000004000109","volume":"40","author":"D Penenberg","year":"2000","unstructured":"Penenberg D, Chung M, Walmsley P, Vashi V (2000) The effects of hepatic impairment on the pharmacokinetics of doxazosin. J Clin Pharm 40:67\u201373","journal-title":"J Clin Pharm"},{"key":"5191_CR25","first-page":"14","volume":"10","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG (2008) Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 10:14","journal-title":"Rev Urol"},{"key":"5191_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.ju.0000097026.43866.cc","volume":"171","author":"CG Roehrborn","year":"2004","unstructured":"Roehrborn CG, Schwinn DA (2004) \u03b11-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029\u20131035","journal-title":"J Urol"},{"key":"5191_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/00005344-198707000-00013","volume":"10","author":"H Shionoiri","year":"1987","unstructured":"Shionoiri H, Yasuda G, Yoshimura H, Umemura S, Miyajima E, Miyakawa T, Takagi N, Kaneko Y (1987) Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 10:90\u201395","journal-title":"J Cardiovasc Pharmacol"},{"key":"5191_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/j.1524-6175.2005.05300.x","volume":"7","author":"DA Sica","year":"2005","unstructured":"Sica DA (2005) Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens 7:757\u2013762","journal-title":"J Clin Hypertens"},{"key":"5191_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/03639040500306328","volume":"31","author":"P Sripalakit","year":"2005","unstructured":"Sripalakit P, Penporn N, Sirada M, Sangla P, Poj J, Saraphanchotiwitthaya A (2005) Bioequivalence evaluation of two formulations of doxazosin tablet in healthy Thai male volunteers. Drug Dev Ind Pharm 31:1035\u20131040","journal-title":"Drug Dev Ind Pharm"},{"key":"5191_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/j.1552-4604.1996.tb04208.x","volume":"36","author":"V Vashi","year":"1996","unstructured":"Vashi V, Chung M, Dias N, Phillips K (1996) Effect of time of administration on the pharmacokinetics and tolerance of doxazosin in healthy male volunteers. J Clin Pharmacol 36:325\u2013331","journal-title":"J Clin Pharmacol"},{"key":"5191_CR31","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/HJH.0000000000000119","volume":"32","author":"T Wolak","year":"2014","unstructured":"Wolak T, Toledano R, Novack V, Sharon A, Shalev A, Wolak A (2014) Doxazosin to treat hypertension: it\u2019s time to take it personally\u2013a retrospective analysis of 19 495 patients. J Hypertens 32:1132\u20131137","journal-title":"J Hypertens"},{"key":"5191_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1517\/14656566.9.4.625","volume":"9","author":"A Wykretowicz","year":"2008","unstructured":"Wykretowicz A, Przemyslaw G, Wysocki H (2008) Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother 9:625\u2013633","journal-title":"Expert Opin Pharmacother"},{"key":"5191_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2165\/00003495-198835050-00003","volume":"35","author":"RA Young","year":"1988","unstructured":"Young RA, Brogden RN (1988) Doxazosin. Drugs 35:525\u2013541","journal-title":"Drugs"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05191-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05191-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:35Z","timestamp":1783907075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05191-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5191"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05191-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human and animal subjects performed by any of the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human or animal participants"}}]}}